Dianthus Therapeutics (DNTH) Non Operating Income (2022 - 2025)
Dianthus Therapeutics' quarterly Non Operating Income came in at -$360000.0 in Q3 2025, down 107.62% year-on-year from $4.7 million in Q3 2024, and down 110.92% quarter-over-quarter from $3.3 million in Q2 2025.
Dianthus Therapeutics has reported Non Operating Income for 4 years, with the latest figure at -$360000.0 in Q3 2025.
- For the quarter ending Q3 2025, Non Operating Income fell 107.62% year-over-year to -$360000.0; the trailing twelve-month figure through Sep 2025 stood at $10.1 million (down 9.46% YoY), and the FY2024 full-year result was $16.9 million, up 28258.33% from the prior year.
- Non Operating Income for Q3 2025 stood at -$360000.0, down from $3.3 million in the prior quarter.
- The five-year high for Non Operating Income was $4.7 million in Q3 2024, with the low at -$2.3 million in Q4 2023.
- Average Non Operating Income over 4 years is $1.6 million, with a median of -$2000.0 recorded in 2022.
- Year-over-year, Non Operating Income tumbled 5216.28% in 2023 and jumped 136633.33% in 2024.
- Tracing DNTH's Non Operating Income over 4 years: stood at -$43000.0 in 2022, then plunged by 5216.28% to -$2.3 million in 2023, then surged by 252.06% to $3.5 million in 2024, then slumped by 110.36% to -$360000.0 in 2025.
- The last three Non Operating Income figures came in at -$360000.0 (Q3 2025), $3.3 million (Q2 2025), and $3.7 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Dianthus Therapeutics | 4.02 Bn | 3.62 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -360,000.00 |
| Jun 30, 2025 | 3.30 Mn |
| Mar 31, 2025 | 3.67 Mn |
| Dec 31, 2024 | 3.48 Mn |
| Sep 30, 2024 | 4.73 Mn |
| Jun 30, 2024 | 4.60 Mn |
| Mar 31, 2024 | 4.10 Mn |
| Dec 31, 2023 | -2.29 Mn |
| Sep 30, 2023 | -15,000.00 |
| Jun 30, 2023 | -23,000.00 |
| Mar 31, 2023 | -3,000.00 |
| Dec 31, 2022 | -43,000.00 |
| Sep 30, 2022 | -2,000.00 |